Takeda, Eisai Look Abroad To Expand Drug Sales With Cancer, Diabetes Products
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers Takeda Pharmaceutical and Eisai plan to expand beyond their home country to take advantage of overseas markets for their drugs. The desire is driven by patents expiring in the next two years on some of the best-selling products. Takeda is about to market a new prostate cancer treatment (leuprorelin) in France, and Eisai has applied in 10 countries in Southeast Asia to market its Glufast (mitiglinide) diabetes drug. Mitsubishi Tanabe Pharma and Shionogi also have plans to market drugs abroad. (Click here for more - a subscription may be required